Hormonal regulation of lipoprotein(a) levels: Effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women

Catherine H. Tuck, Stephen Holleran, Lars Berglund

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Estrogen lowers lipoprotein(a) [Lp(a)] levels, but the mechanisms involved have not been clarified. To address the relationship between estrogenic effects on Lp(a) and serum lipids, and on other plasma proteins of hepatic origin, 15 healthy postmenopausal women participated in a randomized, double-blinded, placebo-controlled, crossover study with 4 weeks of oral conjugated estrogens (0.625 mg/d) and placebo, separated by a 6-week period. Lp(a) levels decreased during estrogen treatment in 14 of the 15 subjects (mean decrease, 23%; P<.001). In response to estrogen, apolipoprotein A-I (apoA-I), HDL cholesterol, and triglyceride levels increased by 12% (P=.001), 11% (P<.001), and 10% (P=.02), respectively. Apolipoprotein B (apoB) and LDL cholesterol levels decreased by 7% (P=.01) and 12% (P=.03), respectively. ApoB, LDL cholesterol, and Lp(a) levels fell within 1 week of treatment, whereas apoA-I and HDL cholesterol levels rose more slowly. Levels of acid α1-glycoprotein (AAG) and haptoglobin (HPT), two hepatically derived acute phase proteins, also decreased during estrogen treatment by 18% (P<.001) and 25% (P=.002), respectively. Although the changes in AAG and HPT in response to estrogen were highly correlated (r=.67, P=.009), we were unable to detect a correlation between change in either acute phase protein and change in Lp(a) (r=-.14 and -.24, P=.64 and .41). The lack of correlation between the changes in two acute phase reactants and Lp(a) suggests different underlying mechanisms for the effects of estrogen on these liver-derived proteins.

Original languageEnglish (US)
Pages (from-to)1822-1829
Number of pages8
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume17
Issue number9
StatePublished - 1997
Externally publishedYes

Fingerprint

Lipoprotein(a)
Estrogen Replacement Therapy
Acute-Phase Proteins
Estrogens
Haptoglobins
Apolipoprotein A-I
Apolipoproteins B
LDL Cholesterol
HDL Cholesterol
Placebos
Conjugated (USP) Estrogens
Liver
Cross-Over Studies
Blood Proteins
Glycoproteins
Triglycerides
Therapeutics
Lipids
Acids
Serum

Keywords

  • Apolipoprotein(a)
  • Conjugated equine estrogens
  • Hormone replacement therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{bf194dc5eec8418bbfc67590a38d6430,
title = "Hormonal regulation of lipoprotein(a) levels: Effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women",
abstract = "Estrogen lowers lipoprotein(a) [Lp(a)] levels, but the mechanisms involved have not been clarified. To address the relationship between estrogenic effects on Lp(a) and serum lipids, and on other plasma proteins of hepatic origin, 15 healthy postmenopausal women participated in a randomized, double-blinded, placebo-controlled, crossover study with 4 weeks of oral conjugated estrogens (0.625 mg/d) and placebo, separated by a 6-week period. Lp(a) levels decreased during estrogen treatment in 14 of the 15 subjects (mean decrease, 23{\%}; P<.001). In response to estrogen, apolipoprotein A-I (apoA-I), HDL cholesterol, and triglyceride levels increased by 12{\%} (P=.001), 11{\%} (P<.001), and 10{\%} (P=.02), respectively. Apolipoprotein B (apoB) and LDL cholesterol levels decreased by 7{\%} (P=.01) and 12{\%} (P=.03), respectively. ApoB, LDL cholesterol, and Lp(a) levels fell within 1 week of treatment, whereas apoA-I and HDL cholesterol levels rose more slowly. Levels of acid α1-glycoprotein (AAG) and haptoglobin (HPT), two hepatically derived acute phase proteins, also decreased during estrogen treatment by 18{\%} (P<.001) and 25{\%} (P=.002), respectively. Although the changes in AAG and HPT in response to estrogen were highly correlated (r=.67, P=.009), we were unable to detect a correlation between change in either acute phase protein and change in Lp(a) (r=-.14 and -.24, P=.64 and .41). The lack of correlation between the changes in two acute phase reactants and Lp(a) suggests different underlying mechanisms for the effects of estrogen on these liver-derived proteins.",
keywords = "Apolipoprotein(a), Conjugated equine estrogens, Hormone replacement therapy",
author = "Tuck, {Catherine H.} and Stephen Holleran and Lars Berglund",
year = "1997",
language = "English (US)",
volume = "17",
pages = "1822--1829",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Hormonal regulation of lipoprotein(a) levels

T2 - Effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women

AU - Tuck, Catherine H.

AU - Holleran, Stephen

AU - Berglund, Lars

PY - 1997

Y1 - 1997

N2 - Estrogen lowers lipoprotein(a) [Lp(a)] levels, but the mechanisms involved have not been clarified. To address the relationship between estrogenic effects on Lp(a) and serum lipids, and on other plasma proteins of hepatic origin, 15 healthy postmenopausal women participated in a randomized, double-blinded, placebo-controlled, crossover study with 4 weeks of oral conjugated estrogens (0.625 mg/d) and placebo, separated by a 6-week period. Lp(a) levels decreased during estrogen treatment in 14 of the 15 subjects (mean decrease, 23%; P<.001). In response to estrogen, apolipoprotein A-I (apoA-I), HDL cholesterol, and triglyceride levels increased by 12% (P=.001), 11% (P<.001), and 10% (P=.02), respectively. Apolipoprotein B (apoB) and LDL cholesterol levels decreased by 7% (P=.01) and 12% (P=.03), respectively. ApoB, LDL cholesterol, and Lp(a) levels fell within 1 week of treatment, whereas apoA-I and HDL cholesterol levels rose more slowly. Levels of acid α1-glycoprotein (AAG) and haptoglobin (HPT), two hepatically derived acute phase proteins, also decreased during estrogen treatment by 18% (P<.001) and 25% (P=.002), respectively. Although the changes in AAG and HPT in response to estrogen were highly correlated (r=.67, P=.009), we were unable to detect a correlation between change in either acute phase protein and change in Lp(a) (r=-.14 and -.24, P=.64 and .41). The lack of correlation between the changes in two acute phase reactants and Lp(a) suggests different underlying mechanisms for the effects of estrogen on these liver-derived proteins.

AB - Estrogen lowers lipoprotein(a) [Lp(a)] levels, but the mechanisms involved have not been clarified. To address the relationship between estrogenic effects on Lp(a) and serum lipids, and on other plasma proteins of hepatic origin, 15 healthy postmenopausal women participated in a randomized, double-blinded, placebo-controlled, crossover study with 4 weeks of oral conjugated estrogens (0.625 mg/d) and placebo, separated by a 6-week period. Lp(a) levels decreased during estrogen treatment in 14 of the 15 subjects (mean decrease, 23%; P<.001). In response to estrogen, apolipoprotein A-I (apoA-I), HDL cholesterol, and triglyceride levels increased by 12% (P=.001), 11% (P<.001), and 10% (P=.02), respectively. Apolipoprotein B (apoB) and LDL cholesterol levels decreased by 7% (P=.01) and 12% (P=.03), respectively. ApoB, LDL cholesterol, and Lp(a) levels fell within 1 week of treatment, whereas apoA-I and HDL cholesterol levels rose more slowly. Levels of acid α1-glycoprotein (AAG) and haptoglobin (HPT), two hepatically derived acute phase proteins, also decreased during estrogen treatment by 18% (P<.001) and 25% (P=.002), respectively. Although the changes in AAG and HPT in response to estrogen were highly correlated (r=.67, P=.009), we were unable to detect a correlation between change in either acute phase protein and change in Lp(a) (r=-.14 and -.24, P=.64 and .41). The lack of correlation between the changes in two acute phase reactants and Lp(a) suggests different underlying mechanisms for the effects of estrogen on these liver-derived proteins.

KW - Apolipoprotein(a)

KW - Conjugated equine estrogens

KW - Hormone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=0030751046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030751046&partnerID=8YFLogxK

M3 - Article

C2 - 9327783

AN - SCOPUS:0030751046

VL - 17

SP - 1822

EP - 1829

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 9

ER -